Рецепт. 2018; : 535-550
Механизмы развития и клинико- патогенетическое значение анемий при хронических воспалительных заболеваниях кишечника (язвенном колите и болезни Крона)
Аннотация
На основании проведенного исследования в статье представлены результаты анализа распространенности анемий у пациентов с воспалительными заболеваниями кишечника (ВЗК), оценка основных факторов риска развития анемии у пациентов с язвенным колитом (ЯК) и болезнью Крона (БК), показаны результаты исследования структуры анемий у пациентов с ВЗК в зависимости от патогенетического механизма их развития. С учетом полученных данных разработан алгоритм по диагностике и тактике терапии анемий у пациентов с ВЗК, адаптированный к условиям Республики Беларусь.
Список литературы
1. Alves R. [et al.] (2014) Anemia in inflammatory bowel disease: prevalence, differential diagnosis and association with clinical and laboratory variables. Sao Paulo Medical Journal, vol. 132, no 3, pp. 140-146.
2. Weiss G. [et al.] (2010) Pathogenesis and treatment of anemia in Inflammatory Bowel Disease.
3. Haematologica, vol. 95, pp. 175-178.
4. Oustamanolakis P. [et al.] (2011) Diagnosing anemia in inflammatory bowel disease: Beyond the established markers. Journal of Crohn’s and Colitis, vol. 5, no 5, pp. 381-391.
5. Gorgun YU., Karatish O., Portyanko A. (2007) Osobennosti korrektsii obmena zheleza pri hronicheskih vospalitel’nih zabolevaniyah kishechnika [Features of iron exchange correction in chronic inflammatory bowel diseases]. Meditsinskie novosti, 11, pp. 82-84.
6. Murawska N. [et al.] (2016) Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases: Pathophysiology, Diagnosis, and Treatment. Inflammatory bowel diseases, vol. 22, no 5, pp. 1198-1208.
7. Basseri R. [et al.] (2013) Hepcidin is a key mediator of anemia of inflammation in Crohn’s disease.
8. Journal of Crohn’s and Colitis, vol. 7, no 8, pp. 286-291.
9. Armitage A. [et al.] (2011) Hepcidin regulation by innate immune and infectious stimuli. Blood, vol. 1, pp. 118-128.
10. Dignass A. [et al.] (2015) European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. Journal of Crohn’s and Colitis, vol. 1, pp. 1-12.
11. Oustamanolakis P. [et al.] (2011) Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease: a case-control study. Annals of Gastroenterology, vol. 24, no 2, pp. 108-114.
12. Abitbol V. [et al.] (2015) Diagnosis of Iron Deficiency in Inflammatory Bowel Disease by Transferrin Receptor-Ferritin Index. Medicine (Baltimore), vol. 94, no 26, pp. 98-105.
13. Kulnigg S. [et al.] (2008) A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose [FERINJECT] randomized controlled trial. The American Journal of Gastroenterology, vol. 103, pp. 1182-1192.
14. Lee T. [et al.] (2012) Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. Journal of Crohn’s and Colitis, vol. 6, pp. 267-275.
15. Kulnigg S. [et al.] (2006) Systematic review: managing anemia in Crohn’s disease. Alimentary Pharmacology & Therapeutics, vol. 24, pp. 1507-1523.
16. Weiss G. [et al.] (2005) Anemia of Chronic Disease. The New England Journal of Medicine, vol. 352, pp. 1011-1023.
17. WHO (1989) Preventing and controlling anemia through primary health care: a guide for health administrators and programme managers. Geneva, World Health Organization.
18. Wilson A. [et al.] (2004) Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. American Journal of Medicine, vol. 116, pp. 44-49.
19. Filmann N. [et al.] (2014) Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-analysis. Inflammatory bowel diseases, vol. 20, no 12, pp. 936-945.
20. Koutroubakis I. [et al.] (2015) Persistent or recurrent anemia is associated with severe and disabling inflammatory bowel disease. Clinical Gastroenterology and Hepatology, vol. 13, no 12, pp. 1760-1766.
21. Akhuemonkhan E. [et al.] (2017) Prevalence and screening for anemia in mild to moderate Crohn’s disease and ulcerative colitis in the United States, 2010-2014. BMJ Open Gastroenterology, vol. 4, no 1, pp. 1-8.
Recipe. 2018; : 535-550
Mechanisms of the development and clinico-pathological significance of anemia in chronic inflammatory bowel diseases (ulcerative colitis and Crohn’s disease)
Abstract
References
1. Alves R. [et al.] (2014) Anemia in inflammatory bowel disease: prevalence, differential diagnosis and association with clinical and laboratory variables. Sao Paulo Medical Journal, vol. 132, no 3, pp. 140-146.
2. Weiss G. [et al.] (2010) Pathogenesis and treatment of anemia in Inflammatory Bowel Disease.
3. Haematologica, vol. 95, pp. 175-178.
4. Oustamanolakis P. [et al.] (2011) Diagnosing anemia in inflammatory bowel disease: Beyond the established markers. Journal of Crohn’s and Colitis, vol. 5, no 5, pp. 381-391.
5. Gorgun YU., Karatish O., Portyanko A. (2007) Osobennosti korrektsii obmena zheleza pri hronicheskih vospalitel’nih zabolevaniyah kishechnika [Features of iron exchange correction in chronic inflammatory bowel diseases]. Meditsinskie novosti, 11, pp. 82-84.
6. Murawska N. [et al.] (2016) Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases: Pathophysiology, Diagnosis, and Treatment. Inflammatory bowel diseases, vol. 22, no 5, pp. 1198-1208.
7. Basseri R. [et al.] (2013) Hepcidin is a key mediator of anemia of inflammation in Crohn’s disease.
8. Journal of Crohn’s and Colitis, vol. 7, no 8, pp. 286-291.
9. Armitage A. [et al.] (2011) Hepcidin regulation by innate immune and infectious stimuli. Blood, vol. 1, pp. 118-128.
10. Dignass A. [et al.] (2015) European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. Journal of Crohn’s and Colitis, vol. 1, pp. 1-12.
11. Oustamanolakis P. [et al.] (2011) Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease: a case-control study. Annals of Gastroenterology, vol. 24, no 2, pp. 108-114.
12. Abitbol V. [et al.] (2015) Diagnosis of Iron Deficiency in Inflammatory Bowel Disease by Transferrin Receptor-Ferritin Index. Medicine (Baltimore), vol. 94, no 26, pp. 98-105.
13. Kulnigg S. [et al.] (2008) A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose [FERINJECT] randomized controlled trial. The American Journal of Gastroenterology, vol. 103, pp. 1182-1192.
14. Lee T. [et al.] (2012) Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. Journal of Crohn’s and Colitis, vol. 6, pp. 267-275.
15. Kulnigg S. [et al.] (2006) Systematic review: managing anemia in Crohn’s disease. Alimentary Pharmacology & Therapeutics, vol. 24, pp. 1507-1523.
16. Weiss G. [et al.] (2005) Anemia of Chronic Disease. The New England Journal of Medicine, vol. 352, pp. 1011-1023.
17. WHO (1989) Preventing and controlling anemia through primary health care: a guide for health administrators and programme managers. Geneva, World Health Organization.
18. Wilson A. [et al.] (2004) Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. American Journal of Medicine, vol. 116, pp. 44-49.
19. Filmann N. [et al.] (2014) Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-analysis. Inflammatory bowel diseases, vol. 20, no 12, pp. 936-945.
20. Koutroubakis I. [et al.] (2015) Persistent or recurrent anemia is associated with severe and disabling inflammatory bowel disease. Clinical Gastroenterology and Hepatology, vol. 13, no 12, pp. 1760-1766.
21. Akhuemonkhan E. [et al.] (2017) Prevalence and screening for anemia in mild to moderate Crohn’s disease and ulcerative colitis in the United States, 2010-2014. BMJ Open Gastroenterology, vol. 4, no 1, pp. 1-8.
